Market news

Cantor upgrades Omeros to Overweight with a $22 price forecast following strong Yartemlea sales and Medicare reimbursement momentum.

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Arnold C Hanish, Director, on August 26, 2026, sold 15,000 shares in Omeros (OMER) for $282,094. Fol

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Thomas J. Cable, Director, on August 20, 2026, sold 15,000 shares in Omeros (OMER) for $276,773. Fol

Detailed price information for Omeros Corp (OMER-Q) from The Globe and Mail including charting and trades.

Detailed price information for Omeros Corp (OMER-Q) from The Globe and Mail including charting and trades.

Omeros (OMER) stock is reacting to a clear shift in its financial story after the company reported second quarter 2026 results that moved from a prior net loss to positive net income. See our latest analysis for Omeros. The latest move to a closing share price of $17.35 comes after a sharp re-rating, with a 30-day share price return of 65.24% and a 1-year total shareholder return of 321.12%. This suggests momentum has accelerated following Omeros' earnings and buyback updates. If you are...

Omeros (OMER) Buy thesis: YARTEMLEA launch beats expectations ($28.5M sales, positive cash flow), faster adoption and lower dilution risk—read now.

Omeros stock rocketed Thursday on second-quarter results for its new treatment for transplant complications.

Omeros (OMER) reported Wednesday Q2 adjusted net earnings of $0.02 per diluted share, swinging from

Moby summary of Omeros Corporation's Q2 2026 earnings call

Gross revenues from YARTEMLEA reached $32.2 million in the quarter, nearly triple the $11.1 million recorded in the first quarter.

Motley Fool Press Release.

Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said.

Detailed price information for Omeros Corp (OMER-Q) from The Globe and Mail including charting and trades.

H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.

Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple. On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab. This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic […]